New Alzheimer's drug enters early human testing

NCT ID NCT07214727

Recruiting now Disease control Sponsor: Alnylam Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 3 times

Summary

This early-stage study tests a new drug called ALN-5288 in 50 adults with mild cognitive impairment or dementia caused by Alzheimer's disease. The drug is given via a spinal injection and aims to safely reduce tau protein levels in the brain. The main goal is to check safety and how the drug moves through the body.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease dementia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER'S DISEASE

Contacts and locations

Locations

Clinical Trial Site
RECRUITING

Montreal, H3G 1H9, Canada
Clinical Trial Site
RECRUITING

Ottawa, K1Z 1G3, Canada
Clinical Trial Site
RECRUITING

Toronto, M3B 2S7, Canada
Clinical Trial Site
NOT_YET_RECRUITING

Toronto, M5T 2S8, Canada
Clinical Trial Site
RECRUITING

's-Hertogenbosch, 5223, Netherlands
Clinical Trial Site
RECRUITING

Amsterdam, 1081 GN, Netherlands
Clinical Trial Site
NOT_YET_RECRUITING

Barcelona, 08036, Spain
Clinical Trial Site
RECRUITING

Madrid, 28040, Spain
Clinical Trial Site
NOT_YET_RECRUITING

Sant Cugat del Vallès, 08190, Spain
Clinical Trial Site
RECRUITING

Glasgow, G51 4TF, United Kingdom
Clinical Trial Site
RECRUITING

London, WC1N 3BG, United Kingdom
Clinical Trial Site
RECRUITING

Sheffield, S10 2JF, United Kingdom
Clinical Trial Site
RECRUITING

Southampton, SO16 6YD, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.